--:--:--LOCAL ·--:--UTC
    US EQUITIESLAST CLOSE
    AAPL$349.21-0.92%
    MSFT$498.30-1.97%
    GOOGL$272.66-3.46%
    AMZN$257.37-3.87%
    NVDA$145.98-3.30%
    META$596.22-3.27%
    TSLA$374.41-2.43%
    NFLX$58.46-2.27%
    BRK.B$572.04-0.45%
    AVGO$346.65-2.09%
    DIS$120.25-1.72%
    SBUX$104.47-4.25%
    MCD$272.35-0.61%
    NKE$34.33-5.45%
    COST$1093.83-0.25%
    WMT$126.04-1.04%
    HD$336.68-0.28%
    KO$96.09-2.04%
    PG$167.85-1.43%
    ORCL$110.57-2.92%
    CRM$183.31-3.72%
    ADBE$221.68-2.00%
    AMD$489.19-7.72%
    INTC$55.72+1.92%
    QCOM$162.01+1.38%
    CSCO$94.70-2.55%
    IBM$223.88-2.03%
    UBER$65.60-4.60%
    ABNB$172.79-4.12%
    SHOP$131.97-5.34%
    PYPL$56.37-2.63%
    COIN$108.87-1.48%
    PLTR$153.68-1.91%
    HOOD$68.65-0.75%
    JPM$320.22-1.20%
    V$402.25-3.12%
    MA$626.50-2.62%
    BAC$48.57-0.70%
    GS$847.53-2.94%
    LLY$1351.12-2.29%
    UNH$330.48-5.55%
    JNJ$267.14-2.04%
    PFE$27.54-1.85%
    XOM$158.93-1.03%
    BA$160.51-1.47%
    BABA$83.31-1.26%
    TSM$352.09-2.90%
    US EQUITIESLAST CLOSE
    AAPL$349.21-0.92%
    MSFT$498.30-1.97%
    GOOGL$272.66-3.46%
    AMZN$257.37-3.87%
    NVDA$145.98-3.30%
    META$596.22-3.27%
    TSLA$374.41-2.43%
    NFLX$58.46-2.27%
    BRK.B$572.04-0.45%
    AVGO$346.65-2.09%
    DIS$120.25-1.72%
    SBUX$104.47-4.25%
    MCD$272.35-0.61%
    NKE$34.33-5.45%
    COST$1093.83-0.25%
    WMT$126.04-1.04%
    HD$336.68-0.28%
    KO$96.09-2.04%
    PG$167.85-1.43%
    ORCL$110.57-2.92%
    CRM$183.31-3.72%
    ADBE$221.68-2.00%
    AMD$489.19-7.72%
    INTC$55.72+1.92%
    QCOM$162.01+1.38%
    CSCO$94.70-2.55%
    IBM$223.88-2.03%
    UBER$65.60-4.60%
    ABNB$172.79-4.12%
    SHOP$131.97-5.34%
    PYPL$56.37-2.63%
    COIN$108.87-1.48%
    PLTR$153.68-1.91%
    HOOD$68.65-0.75%
    JPM$320.22-1.20%
    V$402.25-3.12%
    MA$626.50-2.62%
    BAC$48.57-0.70%
    GS$847.53-2.94%
    LLY$1351.12-2.29%
    UNH$330.48-5.55%
    JNJ$267.14-2.04%
    PFE$27.54-1.85%
    XOM$158.93-1.03%
    BA$160.51-1.47%
    BABA$83.31-1.26%
    TSM$352.09-2.90%
    Plug stock market data into your AI agent — one command: Get your free API key →
    LoginGet API Key
    Company data coverage · NASDAQ

    VTRS — Viatris

    Data coverage, completeness and provenance for Viatris in the Stock Market API — Health Care · Drug Manufacturers - Specialty & Generic.

    NASDAQ USA S&P 500
    Core-field completeness
    88.2%
    Statement periods
    FY2021–FY2025
    Filings archived
    0
    Price collection time
    2026-11-19 22:35 UTC

    Stored price coverage

    Source date: 2026-11-19T21:00:00. Source: yfinance. Collection time is shown separately and does not establish a trade date.

    Recent stored price bars, without investment interpretation
    DateCloseCurrencySourceAdjustment basis
    2026-11-1919.8800USDyfinanceSplit- and dividend-adjusted close
    2026-11-1820.2800USDyfinanceSplit- and dividend-adjusted close
    2026-11-1720.4500USDyfinanceSplit- and dividend-adjusted close
    2026-11-1620.7400USDyfinanceSplit- and dividend-adjusted close
    2026-11-1320.8200USDyfinanceSplit- and dividend-adjusted close

    GET /api/v1/companies/VTRS/prices · Price parameters and adjustment semantics

    No archived filings are currently stored for this listing.

    Dataset availability · Handle missing data

    Profile

    Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

    Employees: 30,000 · Website: https://www.viatris.com · Profile fields populated: 75%

    Data completeness by statement

    Share of stored fields populated in the anchor reporting period (FY2025), primary source sec_edgar. Full per-field breakdown: GET /api/v1/companies/VTRS/financials.

    Income statement9/10 fields (90.0%)
    Balance sheet13/14 fields (92.9%)
    Cash flow5/6 fields (83.3%)
    Per-share2/4 fields (50.0%)

    Financial statement coverage (USD)

    Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.

    PeriodPeriod end RevenueNet incomeTotal assetsTotal equity Fields populatedSource
    FY2025 (USD) 2025-12-31 29 sec_edgar
    FY2024 (USD) 2024-12-31 29 sec_edgar
    FY2023 (USD) 2023-12-31 30 sec_edgar
    FY2022 (USD) 2022-12-31 30 sec_edgar
    FY2021 (USD) 2021-12-31 31 sec_edgar

    Get VTRS data via the API

    The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.

    Company profile

    Name, sector, industry, HQ, employees, market cap, source-tagged.

    GET /api/v1/companies/VTRS

    Financial statements

    Multi-year statements with per-field source tags and completeness.

    GET /api/v1/companies/VTRS/financials

    Computed ratios

    P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.

    GET /api/v1/companies/VTRS/metrics/summary

    News & announcements

    Dated press releases and announcements with source links.

    GET /api/v1/companies/VTRS/news

    Quick start

    Create a free key, then:

    curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/VTRS

    Query VTRS programmatically

    Free tier — instant API key. Built for AI agents.

    Frequently Asked Questions

    What data does the API provide for VTRS?
    Stored coverage for VTRS: price data available, financial statements available, 0 archived filings. REST endpoints are under /api/v1/companies/VTRS; inspect available source metadata for provenance.
    How complete is VTRS's financial data?
    The anchor reporting period (FY2025) has 88.2% of the 17 core statement fields populated. Primary source: sec_edgar.
    What reporting periods are covered for VTRS?
    5 fiscal-year periods are stored (FY2021–FY2025), with per-period field counts and source tags available via /api/v1/companies/VTRS/financials.
    Where does VTRS's data come from?
    Stored price source: yfinance. Primary source for the statement snapshot: sec_edgar. Inspect available period and field source tags at /api/v1/companies/VTRS/financials; missing tags do not establish provenance.